LNTH (Lantheus Holdings) Long-Term Debt: $570 Mil (As of Mar. 2026)


LNTH Lantheus Holdings Inc LNTH
82 GF Score
Price $103.41
GF Value $90.76
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lantheus Holdings Long-Term Debt?

Lantheus Holdings LNTH +0.63% 82 Long-Term Debt is $570 Mil as of Mar. 2026. GuruFocus rates LNTH with a GF Score™ of 82/100 and a GF Value™ of $90.76 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Lantheus Holdings's Long-Term Debt for the quarter that ended in Mar. 2026 was $570 Mil.

Lantheus Holdings's quarterly Long-Term Debt increased from Sep. 2025 ($568 Mil) to Dec. 2025 ($569 Mil) and increased from Dec. 2025 ($569 Mil) to Mar. 2026 ($570 Mil).

Lantheus Holdings's annual Long-Term Debt increased from Dec. 2023 ($562 Mil) to Dec. 2024 ($565 Mil) and increased from Dec. 2024 ($565 Mil) to Dec. 2025 ($569 Mil).

Lantheus Holdings  (NAS:LNTH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Lantheus Holdings Long-Term Debt Related Terms

Lantheus Holdings Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Lantheus Holdings's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantheus Holdings Long-Term Debt Chart

Lantheus Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 163.12 557.71 561.67 565.28 568.68

Lantheus Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 566.10 566.85 567.94 568.68 569.60
LNTH
82GF Score
Lantheus Holdings Inc LNTH
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $570 Mil mean?
Lantheus Holdings (LNTH) has a Long-Term Debt of $570 Mil as of Mar. 2026.
Is Lantheus Holdings' Long-Term Debt too high?
Lantheus Holdings' current Long-Term Debt is $570 Mil. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Long-Term Debt compare to LQDA and HIMS?
Lantheus Holdings' Long-Term Debt of $570 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Lantheus Holdings's current Long-Term Debt is $570 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.76, compared to a current price of $103.41 — trading 13.9% above its estimated fair value. The current Long-Term Debt is $570 Mil. Lantheus Holdings' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Long-Term Debt is $570 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lantheus Holdings (LNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued. The current stock price of $103.41 is trading 13.9% above its estimated GF Value™ of $90.76. GuruFocus considers Lantheus Holdings to be Modestly Overvalued.

Key valuation signals for LNTH:

  • Long-Term Debt: $570 Mil
  • GF Value™: $90.76 vs. price of $103.41 (13.9% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lantheus Holdings Business Description

Other Exchanges 1LNTH:Italy0L8:Germany
Address 201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score

Get the complete analysis for LNTH

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$103.41
Price
$90.76
GF Value